BEIJING--(BUSINESS WIRE)--EdiGene, Inc., a clinical-stage biotechnology company focused on developing transformative gene-editing therapies, announced an oral presentation on the preclinical proof-of-concept (POC) data in non-human primate (NHP) model, including NHP disease model, for LEAPERTM 2.0-based in vivo RNA editing therapies at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held on May 16-20, 2023 in Los Angeles, California. LEAPERTM 2.0 is our proprietary exogenous protein-free RNA base editing technology that uses engineered circular ADAR-recruiting RNAs.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent ?-thalassemia (TDT) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, said it has entered into a research collaboration with Peking University Cancer Hospital to understand gene mutation frequency and clinicopathologic features of patients with advanced colorectal cancer in China, and to advance the study of gene mutations relating to varying response rates to specific targeted therapies. The research result is expected to enable the development of precision medicine for patients pre-screened by specific mutation patterns.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital (BCH) for intellectual property related to methods and compositions for increasing fetal hemoglobin levels by disrupting BCL11A expression at the genomic level to treat hemoglobinopathies.
EdiGene, Inc., a global biotechnology company, and Neukio Biotherapeutics, a biotechnology company, announced an R&D collaboration to develop next-generation immune cell therapies.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company, today announced its Scientific Founder Wensheng Wei’s lab at Peking University has published a research article in Nature Biotechnology on an upgraded version of LEAPER™ (Leveraging endogenous ADAR for programmable editing of RNA) that shows significantly improved efficiency and fidelity of RNA editing in vitro and in vivo.
BEIJING & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, announced a research and development collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology by combining resources and expertise from both sides.
BEIJING & CAMBRIDGE, Mass., November 09, 2021--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, said it has entered into a research collaboration with the University of Wisconsin–Madison as part of the company’s effort of translating proprietary LEAPER™ RNA editing technology into in vivo therapies.